Auph short interest.

Jul 15, 2022 · Biogen has more recently been seen as a potential acquirer of AUPH after a Stat News report said that Biogen is working with Goldman Sachs to find potential targets for the company. Aurinia ( AUPH ...

Auph short interest. Things To Know About Auph short interest.

AUPH - Short squeeze stock short interest data and short selling information for shares of Aurinia Pharmaceuticals Ord. Short interest stock data available for NASDAQ, NYSE, AMEX, OTCBB and Pink Sheets stocks available from shortsqueeze.com.The 5-day price performance for the stock is 13.73%, and 26.09% over 30 days. With these gigs, the year-to-date price performance is 114.82%. Short interest in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) saw shorts transact 17.28 million shares and set a 9.89 days time to cover.Short interest is the volume of POINT Biopharma Global shares that have been sold short but have not yet been covered or closed out. As of October 31st, traders have sold 4,390,000 shares of PNT short. 5.09% of POINT Biopharma Global's shares are currently sold short. Learn More on POINT Biopharma Global's current short interest.Jan 29, 2021 · AUPH Short Interest SETTLEMENT DATE SHORT INTEREST AVG. DAILY SHARE VOLUME DAYS TO COVER 02/12/2021 5,442,521 4,199,973 1.295847. Reply Like. Delmar Price. 26 Feb. 2021. Investing Group.

586. -18.84. 2023-11-22. NP. PSGIX - Blackrock Advantage Small Cap Growth Fund Institutional This fund is a listed as child fund of BlackRock Inc. and if that institution has disclosed ownership in this security, then these positions will not be double counted when calculating total shares and total value.We would like to show you a description here but the site won’t allow us.

Aug 15, 2022 · Analyst’s Disclosure: I/we have a beneficial long position in the shares of AUPH either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my ...

AUPH fails-to-deliver data, short interest, short sale transactions, short volume, borrow rates, short shares availability and much more information. Help Login Register Trading System Live Account. Ticker: ... AUPH. Trading System Performance for AUPH. Appeared in Fisher Transform Cross Up screen on 2023-02-17 2023-02-08: Short Sale Restricted ...The setup was perfect (IMO) with more than 21% Short Interest, a Put/Call ratio of 0.25 (Dec-2023) and a strong earnings + guidance from a grossly oversold position. Long term Bullish, but I will be waiting for the $3.29 gap fill most likely to re-build, unless the Company can formalize a plan to be NASDAQ compliant in short-order. 1969: CARVLive Short Interest data, Utilization, Cost to borrow and much more for Aurinia Pharmaceuticals Inc., Nasdaq:AUPHAurinia Pharmaceuticals Reports First Quarter 2023 Financial and Operational Results Business Wire - Thu May 4, 5:00AM CDT. Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial results for first quarter ended March 31, 2023. Amounts are expressed in U.S. dollars. 9.28.

AUPH Short Positions, Funds Shorting Aurinia Pharmaceuticals Inc ... Short Interest Funds Shorting AUPH Short Transactions Short Volume Fails to Deliver. Options . Options Chain Options Sentiment Options Flow Gamma Exposure Implied Volatility. Filings . SEC Filings - Categorized SEC Filings - Latest Press Releases Exhibits. Financials .

On another thread there us a guy who is misguided and blaming mgmt. Claims short interest is going up. I checked itsv8.5% as of May 15th. We should soon find out if short interest has gone up.

Aurinia Pharmaceuticals (AUPH, $9.25) price may drop as it broke higher Bollinger Band on Nov 20, 2023 Tickeron - Technical Analysis • 6 days ago. This price move could be a signal that AUPH may fall back below the higher band and head toward the middle band. Traders may consider selling the stock, shorting the stock, or exploring put options...Meanwhile, Jefferies analyst Maury Raycroft, with a Buy rating on Aurinia ( AUPH ), has cut the per share target to $29 from $34 to imply a premium of ~142% to the last close. Raycroft attributes ...Learn more about AUPH stock here. Skip to content. Explore Alpha Picks; ... Interest income rose to $3.8 million due to higher yields from increased interest rates. ... cash equivalents, and short ...AUPH - Short squeeze stock short interest data and short selling information for shares of Aurinia Pharmaceuticals Ord. Short interest stock data available for NASDAQ, NYSE, AMEX, OTCBB and Pink Sheets stocks available from shortsqueeze.com.Short Interest: 17.28M (10/31/23)Short Interest Change-0.88%: Percent of Float: 13.23%Short term price changes are just games with the shorts, they have beat this ... A world energy crisis driving a renewed interest in uranium.AUPH short interest is 8.5%. Also see, Alnylam Pharma is said to be a potential target for Novartis. Recommended For You. Comments (34) Newest. Publish. Have a tip? Submit confidentially to our ...

Affimed saw a decline in short interest in the month of November. As of November 15th, there was short interest totaling 1,640,000 shares, a decline of 24.1% from the October 31st total of 2,160,000 shares. Based on an average daily volume of 562,700 shares, the short-interest ratio is currently 2.9 days. View Affimed's Short Interest.Short interest in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) saw shorts transact 17.28 million shares and set a 9.89 days time to cover. Analysts on Wall Street suggest a consensus price target of $13.21, implying an increase of 29.75% to the stock’s recent value.2023-03-14 Short sale volume (not short interest) for $AUPH is 32%. http://shortvolumes.com/?t=AUPH $XLV 48% $AEZS 50% $REGN 54%. 16 Mar 2023 00:36:01WebAurora Cannabis Inc. ACB-T. 10.7%. $29.6. 10.6%. On the 20 most shorted companies by percentage of float table, Canada Goose Holdings Inc. ( GOOS-T) is once again perched at the top, with 32.6 per ...WebAurinia Pharmaceuticals (AUPH) has begun to examine strategic alternatives that could include a potential sale or merger. ... Also, with 11%+ short interest, there should be some "motivated ...

Dec 1, 2023 · The short interest in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) is 17.19 million shares and it means that shorts have 11.64 day(s) to cover. The consensus price target of analysts on Wall Street is $13.21, which implies an increase of 34.6% to the stock’s current value. Artal Group S.A. increased its stake in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Rating) by 33.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,000,000 shares of the company’s stock after buying an additional 500,000 …Web

It seems like the purpose of the document is to formalize the recent changes to the commercial partnership (originally announced here) as well as some of the items from the cooperation agreement released in February; particularly when it comes to the availability of stock warrants that Healios can execute once they achieve approvals for ARDS ... Aurinia Pharmaceuticals AUPH closed the last trading session at $9.04, gaining 22.8% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $13.21 indicates a 46.1% upside potential. The average comprises seven short-term …Aurinia Pharmaceuticals Reports First Quarter 2023 Financial and Operational Results Business Wire - Thu May 4, 5:00AM CDT. Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial results for first quarter ended March 31, 2023. Amounts are expressed in U.S. dollars. 9.28.Nasdaq provides market information on after hours trading daily from 4:15 p.m. ET to 3:30 p.m. ET on the following day. $175.49 -3.58 -2%. NVIDIA Corporation Common Stock. $422.39 -12.81 -2.94% ...Mar 21, 2023 · Biotech stocks are very interest rate sensitive and I suspect once the Federal Reserve pivots and begins cutting interest rates, AUPH and the rest of the sector's stocks will move materially ... Author: u/Yolteotl (Karma: 16452, Created: Feb-2013). AUPH: Best treatment against Lupus nephritis, still widely undervalued, buyout candidate and…Analyst’s Disclosure: I/we have a beneficial long position in the shares of AUPH either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my ...The settlement with Sun Pharma appeared to spark some renewed speculation that the company could be a takeover target again. Dealreporter speculated at the time that Aurinia (AUPH) could be viewed as a takeout candidate with the patent overhang lifted. Aurinia (AUPH) short interest is 10.7%.

Investors in Aurinia Pharmaceuticals (NASDAQ:AUPH) have seen favorable returns of 78% over the past year. Passive investing in index funds can generate returns that roughly …

Mission Statement. The mission of ShortSqueeze® is to provide short interest stock market data and services, so our members will be better informed of short selling in the market, track short interest in stocks, and gain from the advantages of this powerful market data. Tuesday November 28, 2023. 20 Min Delayed.

M&A season started some weeks ago with Trilium / Pfizer, Sanofi bought Kadmon, etc... AUPH is one of the best candidate for the big pharmas. A weird Press Release appeared a couple of weeks ago on different websites, about a 35+ acquisition by a big pharma, it was later asked to be removed by the company from Benzinga. The short interestBiocept, Inc. (NASDAQ:BIOC – Get Free Report) was the target of a significant decline in short interest in July. As of July 15th, there was short interest totalling 26,500 shares, a decline of 6.7% from the June 30th total of 28,400 shares. Approximately 1.8% of the company’s stock are sold short. Based on an average […]WebBack to AUPH Overview. Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions are defined as firms or ...WebIn this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in AUPH / Aurinia Pharmaceuticals Inc. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. The Short Squeeze Score is the result of a sophisticated, multi-factor quantitative model that identifies companies that have the highest risk of experiencing a short squeeze. The scoring model uses a combination of short interest, float, short borrow fee rates, and other metrics. The number ranges from 0 to 100, with higher numbers indicating ... Find the latest Aurinia Pharmaceuticals Inc. (AUPH) stock quote, history, news and other vital information to help you with your stock trading and investing. ... Short Term. 2W - 6W. Mid Term. 6W ...VFS. VinFast Auto Ltd. Ordinary Shares. $34.50 -2.53 -6.83%. MULN. Mullen Automotive, Inc. Common Stock. $0.813 +0.013 +1.62%. Find the latest Insider Activity data for Aurinia Pharmaceuticals Inc ...WebData Link's cloud-based technology platform allows you to search, discover and access data and analytics for seamless integration via cloud APIs. Register for your free account today at data ...Jul 4, 2022 · Still, when we talk about a small-cap biotech that is clearly drawing the interest of some big pharma guys, we can say that AUPH's current valuation is very low, without but surely with buyout ... E131: 2024 Fantasy President picks, debt ceiling agreement, Dollar dominance & moreWebAurinia Pharmaceuticals ( NASDAQ: AUPH) named Dr. Robert Foster as a new board member Thursday as part of an agreement with its major shareholder and investment management firm, MKT Capital Ltd ...

Nov 24, 2023 · View real-time AUPH stock price and news, along with industry-best analysis. Explore Our Brands. WSJ; ... Short Interest Change-0.88%: Percent of Float: 13.23%: Advanced $ 1D. Compare. Peers. Name ... ... short-term outlook for biotechnology or pharmaceuticals companies.” The top ... interest in any company mentioned in this article. Keep reading...Show less.The settlement with Sun Pharma appeared to spark some renewed speculation that the company could be a takeover target again. Dealreporter speculated at the time that Aurinia (AUPH) could be viewed as a takeout candidate with the patent overhang lifted. Aurinia (AUPH) short interest is 10.7%.Short Float / Ratio: 13.17% / 8.88: Perf Quarter-4.23%: Sales: 158.85M: P/S: 8.19: EPS this Y: 31.36%: Inst Trans: 9.16%: Short Interest: 17.19M: Perf Half Y-5.03%: Book/sh: 2.73: P/B: 3.32: EPS next Y: 29.71%: ROA-14.80%: Target Price: 13.21: Perf Year: 76.61%: Cash/sh: 2.35: P/C: 3.85: EPS next 5Y-ROE-18.94%: 52W Range: 4.07 - 12.43: Perf YTD ... Instagram:https://instagram. nvax newshighest yield investmentbest rated gold and silver dealersbest online stock trading app for beginners Aurinia ( AUPH) shares have climbed ~59.7% in the year so far despite a ~2% decline over the past 30 days. The stock has added ~5.8% in the post-market with ~1.5M shares changing hands compared to ... semiconductor indexnft for free The Short Squeeze Score is the result of a sophisticated, multi-factor quantitative model that identifies companies that have the highest risk of experiencing a short squeeze. The scoring model uses a combination of short interest, float, short borrow fee rates, and other metrics. The number ranges from 0 to 100, with higher numbers indicating ... auto zpne Exhibit 99.1 Aurinia Pharmaceuticals Inc. Interim Condensed Consolidated Statements of Financial Position (Unaudited) As at March 31, 2019 (expressed in thousands of US dollars) March 31, 2019 $ December 31, 2018 $ Assets Current assets Cash and cash equivalents 140,359 117,967 Short term investments (note 4) 3,975 7,889 Accounts receivable and ...The setup was perfect (IMO) with more than 21% Short Interest, a Put/Call ratio of 0.25 (Dec-2023) and a strong earnings + guidance from a grossly oversold position. Long term Bullish, but I will be waiting for the $3.29 gap fill most likely to re-build, unless the Company can formalize a plan to be NASDAQ compliant in short-order. 1969: CARVOverview of financial data and news for Aurinia Pharmaceuticals Inc., Nasdaq:AUPH